

# Dimitrios A Pappas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1599236/publications.pdf>

Version: 2024-02-01

43  
papers

2,946  
citations

516710

16  
h-index

302126

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

7089  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
2	Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1487-1494.	0.9	140
3	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e13-e13.	0.9	100
4	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. <i>ACR Open Rheumatology</i> , 2021, 3, 173-184.	2.1	88
5	Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. <i>Arthritis and Rheumatology</i> , 2019, 71, 1987-1996.	5.6	87
6	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
7	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 170-176.	0.9	55
8	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.9	46
9	Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 96-102.	0.9	35
10	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	2.5	34
11	Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 113.	1.9	26
12	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. <i>RMD Open</i> , 2017, 3, e000498.	3.8	25
13	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 2331-2340.	2.2	22
14	Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 134-136.	0.9	22
15	Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. <i>Inflammation</i> , 2013, 36, 279-284.	3.8	16
16	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1797-1805.	0.9	16
17	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
18	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	2.3	16

#	ARTICLE	IF	CITATIONS
19	Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. <i>Rheumatology and Therapy</i> , 2015, 2, 85-96.	2.3	15
20	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1027-1029.	2.0	12
21	Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corona Registry. <i>Journal of Rheumatology</i> , 2019, 46, 1438-1444.	2.0	11
22	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	3.4	10
23	Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corona registry data. <i>Rheumatology International</i> , 2021, 41, 381-390.	3.0	10
24	OP0028...POST-APPROVAL COMPARATIVE SAFETY STUDY OF TOFACITINIB AND BIOLOGIC DMARDS: FIVE-YEAR RESULTS FROM A US-BASED RHEUMATOID ARTHRITIS REGISTRY. , 2019, , .		9
25	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	2.0	9
26	Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry. <i>Rheumatology and Therapy</i> , 2015, 2, 153-164.	2.3	8
27	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corona Registry. <i>Rheumatology and Therapy</i> , 2016, 3, 103-115.	2.3	8
28	Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis Is Unaffected by Comorbidity Burden or Obesity: Data from a US Registry. <i>Journal of Rheumatology</i> , 2020, 47, 1464-1474.	2.0	8
29	Immune modulation of rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 873-889.	3.3	7
30	Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. <i>Rheumatology</i> , 2022, 61, 2792-2804.	1.9	7
31	TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corona CERTAIN Comparative Effectiveness Study. <i>ACR Open Rheumatology</i> , 2022, 4, 65-73.	2.1	7
32	Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corona Registry. <i>American Health and Drug Benefits</i> , 2018, 11, 148-158.	0.5	7
33	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1121-1132.	1.9	6
34	Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2020, 7, 357-369.	2.3	4
35	Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. <i>Rheumatology International</i> , 2021, 41, 585-593.	3.0	4
36	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2021, 91, 107260.	3.8	4

#	ARTICLE	IF	CITATIONS
37	Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open, 2020, 6, e001389.	3.8	4
38	Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatology, 2020, 2, 588-594.	2.1	3
39	Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. Rheumatology and Therapy, 2019, 6, 421-433.	2.3	1
40	Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. Rheumatology International, 2022, 42, 1555-1564.	3.0	1
41	Response to "Correspondence on "Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study" by Zheng et al". Annals of the Rheumatic Diseases, 2022, 81, e225-e225.	0.9	0
42	Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy, 2021, 8, 467-481.	2.3	0
43	Dr. Kremer et al reply. Journal of Rheumatology, 2021, , jrheum.210992.	2.0	0